Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study

Inadequate vaccine response is a common concern among healthcare workers at the frontlines of the COVID-19 pandemic. We aimed to investigate if healthcare workers with history of weak immune response to HBV vaccination are more likely to have weak responses against the BioNTech/Pfizer's BNT162b...

Full description

Saved in:
Bibliographic Details
Published in:PLoS ONE 2022, Vol.17 (5), p.e0268529
Main Authors: Iwamoto, Momoko, Ukimura, Akira, Ogawa, Taku, Kawanishi, Fumiko, Osaka, Naofumi, Kubota, Mari, Mori, Tatsuhiko, Sawamura, Ritsuko, Nishihara, Masami, Suzuki, Tomio, Uchiyama, Kazuhisa
Format: Report
Language:English
Subjects:
Analysis
Antibodies
Complications and side effects
Health aspects
Hepatitis B virus
Immune response
Messenger RNA
Patient outcomes
Prevention
Vaccination
Viral antibodies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inadequate vaccine response is a common concern among healthcare workers at the frontlines of the COVID-19 pandemic. We aimed to investigate if healthcare workers with history of weak immune response to HBV vaccination are more likely to have weak responses against the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine. We prospectively tested 954 healthcare workers for the Anti-SARS-CoV-2 spike (S) protein antibody titers prior to the first and second BNT162b2 vaccination doses and after four weeks after the second dose using Roche's Elecsys.sup.® assay. We calculated the percentage of patients who seroconverted after the first and second doses. We estimated the relative risk of non-seroconversion after the first BNT162b2 vaccine (defined as anti-SARS-CoV-2-S titer
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0268529